# Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

> **NCT00095199** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 939 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed
- **BIOLOGICAL:** Cetuximab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00095199
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 939 (ACTUAL)
- **Last updated:** 2012-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095199, "Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00095199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*